ReviewCurrent oncology reports2010
Response assessment challenges in clinical trials of gliomas.
Review in Current oncology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Journal of neuro-oncology · 2014Guideline
- Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.AJNR. American journal of neuroradiology · 2019Trial
- Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.Journal of neuro-oncology · 2018Trial
- Assessment of intra-observer variability in measurement of high-grade brain tumors.Journal of neuro-oncology · 2012Trial
- Translation and validation of the Neurological Assessment in Neuro-Oncology scale to Brazilian Portuguese.Frontiers in neurology · 2024Article
- Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625.Frontiers in oncology · 2023Article
- Article
- Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.Neuro-oncology · 2021Article
- A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.Acta neuropathologica communications · 2020Article
- Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.AJNR. American journal of neuroradiology · 2018Article
- Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology.PloS one · 2017Article
- Multiparametric MRI and [Frontiers in oncology · 2017Article
- Assessment of Brain Tumor Response: RANO and Its Offspring.Current treatment options in oncology · 2016Review
- Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.European journal of nuclear medicine and molecular imaging · 2016Article
- A new functional classification system (FGA/B) with prognostic value for glioma patients.Scientific reports · 2015Article
- Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma.World neurosurgery · 2015Article
- Current challenges in designing GBM trials for immunotherapy.Journal of neuro-oncology · 2015Review
- 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.International journal of radiation oncology, biology, physics · 2014Article
- Functionalized magnetonanoparticles in visualization of intracranial tumors on MRI.Molecular imaging and biology · 2013Article
- Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.Neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate, reproducible criteria for determining tumor response and progression after therapy are critical for optimal patient care and effective evaluation of novel therapeutic agents. Currently, the most widely used criteria for determining treatment response in gliomas is based on two-dimensional tumor measurements using neuroimaging studies (Macdonald criteria). In recent years, the limitation of these criteria, which only address the contrast-enhancing component of the tumor, have become increasingly apparent. This review discusses challenges that have emerged in assessing response in patients with gliomas and approaches being introduced to address them.
Indexed as
Identifiers
20425610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.